Influenza vaccine for chronic obstructive pulmonary disease (COPD)

Kopsaftis, Zoe; Wood‐Baker, Richard; Poole, Phillippa

doi:10.1002/14651858.cd002733.pub3

Cited by 66 publications

(52 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Physical activity is exceptionally important in reducing exacerbation frequency and mortality rates in patients with COPD [69][70][71][72]. Other interventions include vaccinations against influenza and pneumococcal infections, as these may reduce the risk of exacerbation events and hospital admission [73,74]. Pulmonary rehabilitation is an effective multidisciplinary approach to improving dyspnea and exercise tolerance [75,76].…”

Section: Treatment Optionsmentioning

confidence: 99%

Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance

Tanner

Single

2019

J Innate Immun

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) affects the lives of an ever-growing number of people worldwide. The lack of understanding surrounding the pathophysiology of the disease and its progression has led to COPD becoming the third leading cause of death worldwide. COPD is incurable, with current treatments only addressing associated symptoms and sometimes slowing its progression, thus highlighting the need to develop novel treatments. However, this has been limited by the lack of experimental standardization within the respiratory disease research area. A lack of coherent animal models that accurately represent all aspects of COPD clinical presentation makes the translation of promising in vitro data to human clinical trials exceptionally challenging. Here, we review current knowledge within the COPD research field, with a focus on current COPD animal models. Moreover, we include a set of advantages and disadvantages for the selection of pre-clinical models for the identification of novel COPD treatments.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%

Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance

Tanner

Single

2019

J Innate Immun

View full text Add to dashboard Cite

show abstract

“…The elderly, especially patients with chronic lung diseases, contracting flu or pneumococcal pneumonia, are at a high risk of death. This can be avoided through preventive vaccinations [343][344][345]. The Polish recommendations suggest vaccinating individuals above the age of 50 against pneumococci, stressing the fact that pneumococcal pneumonia in persons additionally affected by chronic lung disease is much more frequent, i.e.…”

Section: Question 24 Should Preventive Vaccinations Be Used In Ipf Pmentioning

confidence: 99%

Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

Piotrowski

Bestry²,

Białas

et al. 2020

Advances in Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Vaccination against vaccine‐preventable respiratory viral infections is effective in COPD. Annual influenza vaccination is recommended in people aged 65 years and older to lower the risk of influenza‐like illness, and in people with COPD to reduce exacerbation rates, with limited, non‐randomized data regarding influenza vaccination in patients with AATD . The antibody response to pneumococcal polysaccharides is preserved in AATD, and pneumococcal vaccination protects against community‐acquired pneumonia and reduces exacerbation rates in the wider group of all patients with COPD …”

Section: Management Of Aatd (Other Than Augmentation Therapy and Surgmentioning

confidence: 99%

Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*

et al. 2020

View full text Add to dashboard Cite

AATD is a common inherited disorder associated with an increased risk of developing pulmonary emphysema and liver disease. Many people with AATD‐associated pulmonary emphysema remain undiagnosed and therefore without access to care and counselling specific to the disease. AAT augmentation therapy is available and consists of i.v. infusions of exogenous AAT protein harvested from pooled blood products. Its clinical efficacy has been the subject of some debate and the use of AAT augmentation therapy was recently permitted by regulators in Australia and New Zealand, although treatment is not presently subsidized by the government in either country. The purpose of this position statement is to review the evidence for diagnosis and treatment of AATD‐related lung disease with reference to the Australian and New Zealand population. The clinical efficacy and adverse events of AAT augmentation therapy were evaluated by a systematic review, and the GRADE process was employed to move from evidence to recommendation. Other sections address the wide range of issues to be considered in the care of the individual with AATD‐related lung disease: when and how to test for AATD, changing diagnostic techniques, monitoring of progression, disease in heterozygous AATD and pharmacological and non‐pharmacological therapy including surgical options for severe disease. Consideration is also given to broader issues in AATD that respiratory healthcare staff may encounter: genetic counselling, patient support groups, monitoring for liver disease and the need to establish national registries for people with AATD in Australia and New Zealand.

show abstract

Influenza vaccine for chronic obstructive pulmonary disease (COPD)

Abstract: Influenza vaccine for chronic obstructive pulmonary disease (COPD) (Review) Kopsa is Z, Wood-Baker R, Poole P Kopsa is Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD).

Cited by 66 publications

References 46 publications

Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance

Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance

Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*

Contact Info

Product

Resources

About